Urinary sodium excretion is the main determinant of mineralocorticoid excretion rates in patients with chronic kidney disease

Nephrology Dialysis Transplantation

Volumn 28, Issue 6, 2013, Pages 1526-1532

  McQuarrie, Emily P ^a,b   Freel, Ellen Marie ^a   Mark, Patrick B ^a,b   Fraser, Robert ^a   Connell, John M C ^c   Jardine, Alan G ^a,b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Aldosterone; Deoxycorticosterone; Diabetes; Glomerulonephritis; Hypertension; Sodium

Indexed keywords

ALDOSTERONE; DEOXYCORTICOSTERONE; ELECTROLYTE; MINERALOCORTICOID; SODIUM; TETRAHYDROALDOSTERONE; TETRAHYDRODEOXYCORTICOSTERONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BIOSYNTHESIS; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ESSENTIAL HYPERTENSION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MASS FRAGMENTOGRAPHY; MEMBRANOUS GLOMERULONEPHRITIS; PHENOTYPE; PRIORITY JOURNAL; SODIUM URINE LEVEL; URINARY EXCRETION;

ALDOSTERONE; DEOXYCORTICOSTERONE; DIABETES; GLOMERULONEPHRITIS; HYPERTENSION; SODIUM;

ALDOSTERONE; COHORT STUDIES; CORTICOSTERONE; CROSS-SECTIONAL STUDIES; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MINERALOCORTICOIDS; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; SODIUM;

EID: 84879876452     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft007     Document Type: Article

References (18)

1. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events and hospitalization. N Engl J Med 2004; 351: 1296-1305
2. Tonelli M, Pfeffer MA. Kidney disease and cardiovascular risk. Annu Rev Med 2007; 58: 123-139
3. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996; 98: 1063-1068
4. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993; 25: 563-575
5. Navaneethan SD, Nigwekar SU, Sehgal AR et al. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009; 4: 542-551
6. Edwards NC, Steeds RP, Stewart PM et al. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol 2009; 54: 505-512
7. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006; 70: 2116-2123
8. Hene RJ, Boer P, Koomans HA et al. Plasma aldosterone concentrations in chronic renal disease. Kidney Int 1982; 21: 98-101
9. McQuarrie EP, Freel EM, Mark PB et al. Urinary corticosteroid excretion predicts left ventricular mass and proteinuria in chronic kidney disease. Clin Sci (Lond) 2012; 123: 285-294
10. Shackleton CH. Mass spectrometry: application to steroid and peptide research. Endocr Rev 1985; 6: 441-486
11. Abdelhamid S, Blomer R, Hommel G et al. Urinary tetrahydroaldosterone as a screening method for primary aldosteronism: a comparative study. Am J Hypertens 2003; 16: 522-530
12. Schjoedt KJ, Andersen S, Rossing P et al. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 2004; 47: 1936-1939
13. Jin Y, Kuznetsova T, Maillard M et al. Independent relations of left ventricular structure with the 24-hour urinary excretion of sodium and aldosterone. Hypertension 2009; 54: 489-495
14. Hammer F, Edwards NC, Hughes BA et al. The effect of Spironolactone upon corticosteroid hormone metabolism in patients with early stage chronic kidney disease. Clin Endocrinol (Oxf) 2010; 73: 566-572
15. Berl T, Katz FH, Henrich WL et al. Role of aldosterone in the control of sodium excretion in patients with advanced chronic renal failure. Kidney Int 1978; 14: 228-235
16. Bomback AS, Kshirsagar AV, Ferris ME et al. Disordered aldosterone- volume relationship in end-stage kidney disease. J Renin Angiotensin Aldosterone Syst 2009; 10: 230-236
17. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001; 345: 1689-1697
18. McCurley A, Jaffe IZ. Mineralocorticoid receptors in vascular function and disease. Mol Cell Endocrinol 2012; 350: 256-265